ViroPharma’s Phase 3 Setback – Analyst Blog
Posted on Monday, February 9th, 2009 | In Stocks to Watch
Contributed by: Zacks Market Commentaries (http://www.zacks.com/) -
This morning, ViroPharma (VPHM) announced that its phase III trial evaluating maribavir as a prophylaxis in allogenic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint of a reduction in cytomegalovirus (CMV) disease within 6 months.
We are clearly disappointed in the outcome of the phase III maribavir SCT trial. Maribavir was key to our investment thesis given the expected launch of a generic Vancocin product potentially during the second half of 2009.
As a result, we are downgrading our rating to Hold and taking our price target down to $8 per share. We will have a full report out shortly.
“VPHM” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.